Prognostic value of lymph node involvement in ovarian serous borderline tumors - 19/08/11
, Philippe Morice, MD, PhD a, Catherine Uzan, MD, PhD aRésumé |
Objective |
This study was conducted to evaluate the prognosis value of lymph node involvement (LN positive) lymph node involvement for borderline ovarian tumor (BOT).
Study Design |
This was a retrospective study on 49 patients treated at our institution for advanced-stage serous BOT (International Federation of Gynecology and Obstetrics [FIGO] III or IV). Pathological characteristics and survival were compared according to the lymph node status. The same analysis was performed on 1503 patients of the Surveillance, Epidemiology, and End Results (SEER) database.
Results |
In our institution, 14 patients were LN positive. Eight patients have been upstaged after lymph node dissection. No patient has died during follow-up (median 53 months). LN positivity was not associated with recurrence. In the SEER registry, 93 patients (6.2%) had LN positivity. These patients were younger and with more advanced local extension. Survival curves were similar after adjustment for FIGO stage.
Conclusion |
Lymph node involvement does not appear as a prognosis factor for advanced-stage BOT.
Le texte complet de cet article est disponible en PDF.Key words : advanced stage, borderline ovarian tumor, endosalpingiosis, lymphadenectomy, prognosis
Plan
| Cite this article as: Lesieur B, Kane A, Duvillard P, et al. Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol 2011;204:438.e1-7. |
Vol 204 - N° 5
P. 438.e1-438.e7 - mai 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
